• Our products

  • 1


VIMPAT® (Lacosamide) is an antiepileptic drug approved as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy. VIMPAT® is a functionalized amino acid, the antiepileptic effects of which appear to be due to a novel mode of action, namely the selective enhancement of slow inactivation of voltage-gated sodium channels.

LATUDA® (Lurasidone) is a once-daily oral atypical antipsychotic indicated for the treatment of schizophrenia in adults aged 18 years and over. In addition to its well-demonstrated efficacy, LATUDA® with its favorable metabolic safety profile may be a solution for unmet medical needs of schizophrenia

NEUPRO® is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on-off” fluctuations).

*For full prescribing information please refer to your locally approved label*


  • 1